OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-510-7750515
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees16
Next Earnings Date4/1/2019 (Estimated)
OptionableNot Optionable
OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions
What is OncoCyte's stock symbol?
OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."
How were OncoCyte's earnings last quarter?
OncoCyte Corp (NYSEAMERICAN:OCX) released its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.12) EPS for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.02. View OncoCyte's Earnings History.
When is OncoCyte's next earnings date?
What price target have analysts set for OCX?
4 analysts have issued 12 month price targets for OncoCyte's stock. Their predictions range from $6.00 to $7.00. On average, they anticipate OncoCyte's stock price to reach $6.6667 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price. View Analyst Price Targets for OncoCyte.
What is the consensus analysts' recommendation for OncoCyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.
Has OncoCyte been receiving favorable news coverage?
Media coverage about OCX stock has trended somewhat positive on Thursday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. OncoCyte earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Are investors shorting OncoCyte?
OncoCyte saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,256,555 shares, an increase of 243.9% from the January 15th total of 365,397 shares. Based on an average daily volume of 4,949,763 shares, the days-to-cover ratio is currently 0.3 days. Approximately 6.8% of the company's stock are short sold. View OncoCyte's Current Options Chain.
Who are some of OncoCyte's key competitors?
Some companies that are related to OncoCyte include Resverlogix (RVX), Mesoblast (MSB), Theratechnologies (TH), Emerald Health Therapeutics (EMH), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), 22nd Century Group (XXII), IMV (IMV), Enochian Biosciences (ENOB), Kodiak Sciences (KOD), IMV (IMV), Monash IVF Group (MVF), ProMetic Life Sciences (PLI) and Emblem (EMC).
What other stocks do shareholders of OncoCyte own?
Who are OncoCyte's key executives?
OncoCyte's management team includes the folowing people:
- Mr. William Annett, Pres, CEO & Director (Age 65)
- Mr. Mitchell S. Levine, Chief Financial Officer
- Dr. Lyndal K. Hesterberg Ph.D., Sr. VP of R&D
- Mr. Albert P. Parker II, Chief Operating Officer
- Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)
How do I buy shares of OncoCyte?
Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoCyte's stock price today?
One share of OCX stock can currently be purchased for approximately $4.00.
How big of a company is OncoCyte?
OncoCyte has a market capitalization of $205.59 million. OncoCyte employs 16 workers across the globe.
What is OncoCyte's official website?
How can I contact OncoCyte?
OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-7750515.
MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
